Epinephrine is the only proven anaphylaxis treatment to reduce the risk of hospitalization and death. However, only 21% of ...

Pmv Pharmaceuticals, Inc. ( ($PMVP) ) has released its Q4 earnings. Here is a breakdown of the information Pmv Pharmaceuticals, Inc. presented to ...

A groundbreaking consensus report on anaphylaxis – the severe reaction some people experience from bee stings, peanut butter ...

The report provides a comprehensive analysis of global trends, challenges, and emerging opportunities in the Hepatitis B clinical research ecosystem. The report leverages Novotech’s extensive ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) has released its 2024 financial results and provided an update on its ...

In a regulatory filing, BioNTech (BNTX) disclosed that the U.S. Food and Drug Administration has informed BioNTech SE that it has placed a ...

PESG Research releases an update following groundbreaking clinical evaluation results: Inspira Technologies* (NASDAQ: IINN) ...

Scientific Advocacy and Clinical Evidence The clinical need for ... the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the ...

The study looked at patients with leukaemia, which occurs in bone marrow, and lymphoma, which affects the lymphatic system.

Influenza A and B patients had similar death rates by 90 days (13.4% vs 8.7%, respectively) and proportions of radiologic ...

Highlighted potential long-term benefits of INB-200. As of October 18, 2024, five patients remained alive, three patients had ...

Final analysis from IGNITE Phase 2 clinical trial planned for second quarter of 2025: The Company plans to report the final ...